Alterations in Hydrocortisone Pharmacokinetics in a Patient With Congenital Adrenal Hyperplasia Following Bariatric Surgery
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
Management of adult patients with classic congenital adrenal hyperplasia (CAH) is challenging and often complicated by obesity, metabolic syndrome, and adverse cardiovascular risk. Alterations in weight can influence cortisol kinetics. A 19-year-old woman with classic CAH and morbid obesity experienced persistent elevations of androgen levels while receiving oral glucocorticoid therapy. Control of adrenal androgens was improved with continuous subcutaneous hydrocortisone infusion therapy, but obesity-related comorbidities persisted. After undergoing sleeve gastrectomy, the patient experienced dramatic weight loss, with improvement in insulin sensitivity and fatty liver in the postbariatric period. Cortisol clearance studies performed to evaluate changes in hydrocortisone dose requirements showed marked alternations in cortisol pharmacokinetics with decreases in volume of distribution and cortisol clearance, along with an increase in area under the curve for cortisol. Hydrocortisone dose was subsequently decreased 34% by 15 months after surgery. Effective control of androgen excess on this lower hydrocortisone dose was achieved and continues 27 months after surgery. This case highlights obesity-related complications of glucocorticoid replacement therapy in the management of CAH. Individual patient factors, such as fatty liver disease and insulin resistance, can have a clinically important effect on cortisol metabolism. Bariatric surgery was a safe and effective treatment of obesity in this patient with CAH and should be considered for patients with CAH and multiple obesity-related comorbidities.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The presence of obesity, insulin resistance and metabolic syndrome adds another tier of challenge as these chronic comorbidities influence glucocorticoid pharmacokinetics and hence hormonal management in CAH85.”
From Management challenges and therapeutic advances in congenital adrenal hyperplasia (2022) · cites this paper as [85]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Speiser, P. W., Azziz, R., Baskin, L. S., Ghizzoni, L., Hensle, T. W., Merke, D. P., Meyer-Bahlburg, H. F. L., Miller, W. L., Montori, V. M., Oberfield, S. E., et al. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2631 · Cited by 1,468
Self-citationObesity and Gender Influence Cortisol Secretion and Metabolism in Man
Andrew, R., Phillips, D. I. W., & Walker, B. R. (1998) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.83.5.1806 · Cited by 360
Falhammar, H., Frisén, L., Hirschberg, A. L., Norrby, C., Almqvist, C., Nordenskjöld, A., & Nordenström, A. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-2093 · Cited by 204 · cited 1×
“CAH have excess cardiovascular and metabolic morbidity, including obesity, hypertension, and insulin resistance [4].”
BackgroundMallappa, A., Sinaii, N., Kumar, P., Whitaker, M. J., Daley, L.-A., Digweed, D., Eckland, D. J. A., Van Ryzin, C., Nieman, L. K., Arlt, W., et al. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-3809 · Cited by 167 · cited 1×
“Circadian cortisol replacement with a modified-release form of oral hydrocortisone (Chronocort; Diurnal, Cardiff, United Kingdom) and continuous subcutaneous hydrocortisone infusion (CSHI) improve control of adrenal androgens using similar or lower glucocorticoid doses than conventional glucocorticoid formulations [2,…”
BackgroundSelf-citationPasquali, R. (2012) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2012.06569.x · Cited by 131
A Switch in Hepatic Cortisol Metabolism across the Spectrum of Non Alcoholic Fatty Liver Disease
Ahmed, A., Rabbitt, E., Brady, T., Brown, C., Guest, P., Bujalska, I. J., Doig, C., Newsome, P. N., Hubscher, S., Elias, E., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0029531 · Cited by 115 · cited 2×
“Changes in cortisol-cortisone metabolism in the liver, adipose tissue, and skeletal muscle have been implicated in the pathogenesis of nonalcoholic fatty liver disease, and tissue-specific dysregulation of glucocorticoid metabolism in the liver and fat may link insulin resistance and fatty liver with obesity [7, 8].”
BackgroundNella, A. A., Mallappa, A., Perritt, A. F., Gounden, V., Kumar, P., Sinaii, N., Daley, L.-A., Ling, A., Liu, C.-Y., Soldin, S. J., et al. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-1916 · Cited by 91 · cited 3×
“Circadian cortisol replacement with a modified-release form of oral hydrocortisone (Chronocort; Diurnal, Cardiff, United Kingdom) and continuous subcutaneous hydrocortisone infusion (CSHI) improve control of adrenal androgens using similar or lower glucocorticoid doses than conventional glucocorticoid formulations [2,…”
BackgroundMethodSelf-citationBryan, S. M., Honour, J. W., & Hindmarsh, P. C. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-0630 · Cited by 75
Holt, H. B., Wild, S. H., Postle, A. D., Zhang, J., Koster, G., Umpleby, M., Shojaee-Moradie, F., Dewbury, K., Wood, P. J., Phillips, D. I., et al. (2007) · Diabetologia · doi:10.1007/s00125-007-0629-9 · Cited by 48 · cited 2×
“Although obesity, insulin resistance, and fatty liver often occur together, increased cortisol clearance is associated with decreased insulin sensitivity, independent of body fat and fatty liver [6].”
BackgroundMallappa, A., Nella, A. A., Sinaii, N., Rao, H., Gounden, V., Perritt, A. F., Kumar, P., Ling, A., Liu, C., Soldin, S. J., et al. (2018) · Clinical Endocrinology · doi:10.1111/cen.13813 · Cited by 45
Self-citation
Cited by
Management challenges and therapeutic advances in congenital adrenal hyperplasia
Mallappa, A., & Merke, D. P. (2022) · Nature Reviews Endocrinology · doi:10.1038/s41574-022-00655-w · Cited by 113
Self-citationCentral adrenal insufficiency in children and adolescents
Patti, G., Guzzeti, C., Di Iorgi, N., Maria Allegri, A. E., Napoli, F., Loche, S., & Maghnie, M. (2018) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2018.03.012 · Cited by 75
Mallappa, A., Nella, A. A., Sinaii, N., Rao, H., Gounden, V., Perritt, A. F., Kumar, P., Ling, A., Liu, C., Soldin, S. J., et al. (2018) · Clinical Endocrinology · doi:10.1111/cen.13813 · Cited by 45
Self-citationSarafoglou, K., Merke, D. P., Reisch, N., der Grinten, H. L. C., Falhammar, H., & Auchus, R. J. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad134 · Cited by 35
Self-citationCardiometabolic Aspects of Congenital Adrenal Hyperplasia
Krysiak, R. G., der Grinten, H. L. C., Reisch, N., Touraine, P. A., & Falhammar, H. (2024) · Endocrine Reviews · doi:10.1210/endrev/bnae026 · Cited by 26
Impact of Bariatric Surgery in the Short and Long Term: A Need for Time-Dependent Dosing of Drugs
Lau, C., van Kesteren, C., Smeenk, R. M., Huitema, A. D. R., & Knibbe, C. A. J. (2023) · Obesity Surgery · doi:10.1007/s11695-023-06770-5 · Cited by 17
de Heide, L. J. M., de Boer, H. H. R., van Borren, M. M. G. J., Emous, M., Aarts, E. O., & de Boer, H. (2018) · Journal of the Endocrine Society · doi:10.1210/js.2018-00239 · Cited by 13
Flokas, M. E., Yang, L., Middleton, K. R., Kollender, S., Parker, M., Sukin, C., Persky, R., & Merke, D. P. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae309 · Cited by 6
Self-citationCasteràs, A., Fidilio, E., Comas, M., Zabalegui, A., Flores, V., Giralt, M., Troyano, N. D., Ferrer, R., Vilallonga, R., Ciudin, A., et al. (2025) · European Journal of Endocrinology · doi:10.1093/ejendo/lvaf053 · Cited by 5
Vidmar, A. P., Kaiser, L., Martin, M. J., Abel, S. A., Kim, A. G., Weitzner, M., Muñoz, C. E., Fisher, L. K., Kim, M. S., & Samakar, K. (2025) · Journal of Medical Case Reports · doi:10.1186/s13256-025-05047-y · Cited by 4
Lenney, M., Kopp, B. J., & Erstad, B. L. (2022) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxac156 · Cited by 4
Zatsepina, E. A., Samoilov, V. S., Volynkina, A. P., Stepanenko, A. V., & Novichikhina, E. E. (2023) · Problems of Endocrinology · doi:10.14341/probl13206 · Cited by 5
Hubska, J., Roszkowska, Z., Bobrowicz, M., Iwaniuk, S., Rak, B., & Ambroziak, U. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1581681 · Cited by 3
Romo, K. G., Shu, S., Iqbal, Q. Z., & Uwaifo, G. I. (2024) · JCEM Case Reports · doi:10.1210/jcemcr/luae018
Obesity in Classic Congenital Adrenal Hyperplasia: Mechanisms, Complications and Management
Mu, J., Li, Y. J., Sun, M., Li, Y. J., Li, P., & Zou, H. (2026) · Clinical Endocrinology · doi:10.1111/cen.70155
The evolution of new approaches to the treatment of congenital adrenal hyperplasia
Merke, D. P., & Auchus, R. J. (2026) · Endocrine Reviews · doi:10.1210/endrev/bnag033
Self-citation
Metadata
- Authors
- Mallappa, A., Nella, A. A., Kumar, P., Brooks, K. M., Perritt, A. F., Ling, A., Liu, C.-Y., & Merke, D. P.
- Affiliations
- National Institutes of Health (US)
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (US)
- Corresponding author
- Merke, Deborah P.
- ORCID
- Venue
- Journal of the Endocrine Society
- Publisher
- The Endocrine Society
- Published
- 2017-06-21
- Volume
- 1
- Issue
- 7
- Pages
- 994-1001
- ISSN
- 2472-1972 (ISSN-L)
- PMC
- PMC5686643
- OpenAlex
- W2653937184
- Cited by
- 16
- References
- 12
- Citations by year
- 2026: 2 · 2025: 3 · 2024: 3 · 2023: 3 · 2022: 2 · 2018: 3
- FWCI
- 0.65
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- public-domain
- creativecommons.org/publicdomain/zero/1.0/ (vor)
- Locations
- Journal of the Endocrine Society (publishedVersion, public-domain)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Sexual Differentiation and Disorders
- Health Sciences › Medicine › Reproductive Medicine › Ovarian function and disorders
- Keywords
- classic congenital adrenal hyperplasia, bariatric surgery, sleeve gastrectomy, morbid obesity, cortisol clearance, glucocorticoid dose reduction, hyperandrogenism, insulin resistance, hepatic steatosis, weight loss
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.